INmune Bio (INMB) Q3 2026 earnings review
INmune Bio lowers its spending, but drug filings slip again
INmune Bio, a drug developer with no product sales, cut its operating costs while pushing back its key regulatory filings again. Quarterly operating expenses fell by a third to $5 million, and the firm paid down nearly $3 million in past-due supplier bills. Chief executive David Moss moved the UK application for Ebstrocel, its treatment for a rare skin-blistering disease, to early February 2027 and sold new shares in October to fund the business through next autumn.
| Operating expenses | $5.0M −33% from a year ago |
|---|---|
| Cash and equivalents (Sept 30) | $16.3M plus $4.5M gross raised in October |
| UK Ebstrocel filing target | Early Feb 2027 slipped from Q3 or early Q4 2026 |
| Cash runway outlook | Through Q3 2027 extended from Q2 2027 after October raise |
⚖️ Verdict: 🔴 Bearish
The story got worse because every regulatory filing date slipped again while dilution continued. Pushing the UK application to February and the US filing to mid-2027 means the October share sale extended cash only to the third quarter of 2027, right when a mid-2027 UK decision and a license fee come due. On the positive side, the company froze spending on its XPro inflammation drug and signed a distribution deal with Uniphar for early patient access.
The question now is whether the February UK filing holds and leaves enough cash to reach commercial sales without another share sale. Either the complete application wins mid-2027 approval and early patient access brings in cash, or review delays and license payments force another financing first. The February 2027 filing and subsequent regulator validation will tell.
🐂 Bull Case
Pre-Application Filing and Uniphar Deal Advance Ebstrocel
Ebstrocel, INmune Bio's umbilical cord cell therapy for a genetic skin-blistering disease called RDEB, took two practical steps toward market. On October 20, the biotechnology group sent its final pre-application package to the UK medicines regulator. It also signed an agreement with healthcare distributor Uniphar to supply the treatment on a named-patient basis in Europe, the Middle East, and North Africa.
Named-patient programs let doctors request an unapproved medicine for individual patients, which can generate sales "before full commercial approval in individual markets". Meanwhile, progress at the UK factory allowed chief executive David Moss to plan a single complete application "in place of the previously planned rolling review". A patent application covering the cell platform until at least 2045 also entered the US review phase.
What to watch: formal acceptance of the complete UK application in the first quarter of 2027. Acceptance without requests for new clinical trials would confirm that the regulator agrees with the company's manufacturing and trial package.
Lower Trial Spending Cut Operating Losses
Winding down older clinical trials has lowered INmune Bio's regular spending. Total operating expenses dropped 32.6% from a year ago to $5.0 million in the third quarter. Research and development costs, which pay for laboratory work and patient trials, fell 35.3% to $3.2 million. General and administrative overhead, which covers executive pay and legal bills, declined 27.5% to $1.8 million.
Foreign government tax refunds cushioned the cash balance further. The immunology company collected $4.2 million from Australia's research rebate program in July, following $0.4 million from a UK program in June. By our math, third-quarter operating cash outflow was $3.4 million, down from $5.4 million in the same period last year, because the Australian refund offset ongoing bill payments.
What to watch: fourth-quarter operating cash outflow, when no large tax refund arrives. A quarterly outflow near $3.5 million would show that the lower cost structure holds on its own.
🐻 Bear Case
Every Ebstrocel Filing Target Slipped Again
"INmune Bio is approaching regulatory milestones for Ebstrocel that can establish our first commercial product," chief executive David Moss said. Yet every regulatory target moved back again this quarter. After feedback from the UK regulator on the October pre-submission package, "Following agency feedback, INmune Bio plans to submit a complete MAA in early February 2027".
- UK application target: early February 2027, pushed back from the third or early fourth quarter of 2026
- US application target: mid-2027, pushed back from the first quarter of 2027
- European Union application: deferred indefinitely, after previously targeting the first quarter of 2027
This marks the sixth consecutive quarter that the drug developer has delayed its lead filing timetable. In the US, the company has only hired regulatory advisors to request a preliminary meeting with the Food and Drug Administration, while "prioritizing its U.S. submission ahead of a European Medicines Agency filing". Because the company has zero revenue, each delay burns cash without bringing product sales closer.
What to watch: the UK application filing in early February 2027. Another delay past February would push potential mid-2027 approval beyond the company's current cash limit.
Cash Still Runs Out Near Potential Approval
INmune Bio ended September with $16.3 million in cash, missing the $19.0–21.0 million range implied by our math from its prior burn outlook. Although it collected $4.2 million in Australian tax rebates in July, the business spent $6.6 million in underlying operating cash by our math as it paid down $2.9 million of overdue supplier bills.
To refill its bank account, the clinical-stage firm sold 3 million shares and 3 million warrants in October for $4.5 million in gross proceeds, or $1.50 per unit by our math. That lifted the share count by 12.1% from June to 31 million shares, but extended the cash outlook by just one quarter, "sufficient to fund operations through the third quarter of 2027". Because UK approval is now targeted for mid-2027 and triggers a license payment of up to 6 million British pounds, cash still runs out right at approval.
What to watch: financing terms in the first half of 2027. Raising money before the UK regulator rules on Ebstrocel would dilute shareholders again before the drug proves it can win approval.
Risks This Quarter Didn't Answer
Four standing risks and clinical commitments received no clear answers in the third-quarter release, while the company froze spending on its other drugs.
- Phase 3 confirmatory study: previously scheduled to treat its first patient in the fourth quarter of 2026, but dropped from the release's milestone table without explanation.
- Single-product reliance and trial data: freezing XPro spending leaves the company entirely reliant on Ebstrocel, yet the release still gives no numerical pain or itch scores from its small crossover study.
- US pediatric voucher eligibility: pushing the US filing to mid-2027 leaves open whether the company can still qualify for a regulatory voucher, and US donor cell validation remains unconfirmed.
- UK pricing and Partner search: National Health Service reimbursement remains unnegotiated, and no pharmaceutical partner has stepped in to fund XPro.
👓 Other Themes
INmune Bio Freezes XPro Spending and Pivots
Last quarter, INmune Bio planned to submit a late-stage Alzheimer's trial protocol for XPro, its inflammation drug, by year-end. Instead, it froze capital for new XPro trials "until Ebstrocel™ is approved or dedicated XPro™ resources are in place". It partnered with Quantum Computing Inc. to search biomedical datasets for a "small, fast and capital-efficient program" in rare pediatric diseases.
💲 Other KPIs
Fell 71.7% from $7.8 million at the end of 2025, and dropped by $2.9 million in the third quarter alone from $5.1 million in June. Paying off these unpaid bills from past clinical trials consumed $5.5 million in cash over the first nine months of 2026.
Declined 72.6% from $4.4 million in the second quarter after the Australian government paid out $4.2 million in July. Research tax credit receivables are government refunds earned on past trial spending that have not yet arrived in cash, so the smaller balance means smaller cash refunds ahead.
🔮 Guidance
Raised. Management extended its cash horizon by one quarter after raising $4.5 million in October, which brought pro-forma cash to $20.8 million by our math. That implies maximum cash spending of about $5.2 million per quarter over the next four quarters, covering the mid-2027 UK approval target.
Cut. The target date slipped by about four months, pushing potential UK approval from the second quarter of 2027 to mid-2027. It is the sixth time INmune Bio has pushed back its UK filing schedule since first targeting mid-2026, though it will now file a complete application rather than a rolling one.
Cut. The US regulatory filing moved back from the first quarter of 2027 to mid-2027, and remains contingent on feedback from a planned preliminary meeting with the Food and Drug Administration. The company has moved this target back five times since originally planning a filing in 2025 or early 2026.
❓ Key Questions
Why did the UK application slip to February 2027?
INmune Bio said agency feedback on its October pre-submission package led to a complete filing in early February 2027 instead of a rolling review. Investors need to know what specific items the regulator asked the company to complete before filing.
What happened to the Phase 3 confirmatory trial start?
Last quarter's milestones targeted treating the first patient in the open-label Phase 3 Ebstrocel study in the fourth quarter of 2026. That milestone disappeared from this release's schedule without comment.
Does the Q3 2027 cash plan include the approval fee?
First marketing approval of Ebstrocel triggers a license milestone of up to 6 million British pounds (about $8 million). Management did not state whether its cash plan through the third quarter of 2027 covers that payment alongside mid-2027 UK approval.
Why abandon the Q4 Alzheimer's protocol for XPro?
After winning Food and Drug Administration alignment for a Phase 2b/3 Alzheimer's trial and guiding for a fourth-quarter protocol submission, the company froze XPro spending and pivoted to analyzing rare pediatric diseases. Was this driven by failed partnership talks?